This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.
We are interested in conducting research that will benefit the people of West Virginia. The application of what we learn from research is vital to the improvement of the health, quality of service, and patient care throughout West Virginia. Vandalia Health Charleston Area Medical Center is dedicated to providing the latest in new therapies and applications.
See below for a categorized listing of clinical trials currently underway at CAMC. You can also view all clinical trials.
This Phase III clinical trial is for patients aged 5 to 60 years old who have been recently diagnosed with early-stage (Stage I or II) classical Hodgkin lymphoma (cHL) that hasn't been treated yet.
The study wants to see if a new treatment approach is better than the standard one. The new approach adds two immune system-boosting medicines (brentuximab vedotin and nivolumab) to regular chemotherapy and possibly radiation.
The goal is to find out if adding these extra medicines helps people survive longer, or if it causes fewer bad side effects compared to using only the standard treatment.
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
The primary objective of this study is to assess the effect of adjuvant treatment with olaparib on Invasive Disease-Free Survival (IDFS).
Note: This study is closed to accrual, meaning that the research team is no longer enrolling new subjects.